SCHEMBL1778265

SCHEMBL1778265

COc1ccc2c(c1)c(-c1cc3c(-c4cccnc4)ccnc3n1S(=O)(=O)c1ccc(C)cc1)cn2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.41
LCK P06239 1/20 0.41
IGF1R P08069 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
CDK7 P50613 1/20 0.41
BTK Q06187 1/20 0.41
LRRK2 Q5S007 1/20 0.41
AURKB Q96GD4 1/20 0.41
NR4A2 P43354 1/20 0.41
EED O75530 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
CKS1B P61024 2/20 0.39
SKP2 Q13309 2/20 0.39
SCN9A Q15858 1/20 0.39
CYP11B1 P15538 4/20 0.38
CYP11B2 P19099 4/20 0.38
CYP17A1 P05093 2/20 0.38
CYP3A4 P08684 1/20 0.38
HTR6 P50406 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1778063 0.92 JAK2 (0.41) JAK2LCKIGF1RGSK3AGSK3B
SCHEMBL1778760 0.85 MAPT (0.43) NR4A2PTGDR2CKS1BSKP2CYP11B1
SCHEMBL1777155 0.85 JAK2 (0.43) JAK2LCKIGF1RGSK3AGSK3B
SCHEMBL1778388 0.84 JAK2 (0.41) JAK2LCKIGF1RGSK3AGSK3B
SCHEMBL1777441 0.83 LMNA (0.43) JAK2LCKIGF1RGSK3AGSK3B
SCHEMBL1779630 0.83 HTR6 (0.44) JAK2LCKIGF1RGSK3AGSK3B
SCHEMBL1779126 0.82 HTR6 (0.40) JAK2LCKIGF1RGSK3AGSK3B
SCHEMBL1780223 0.82 BRD4 (0.41) JAK2LCKIGF1RGSK3AGSK3B
SCHEMBL5408823 0.80 HTR6 (0.41) JAK2LCKIGF1RGSK3AGSK3B
SCHEMBL1778171 0.79 EED (0.40) EEDHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943616-B2 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders AVENTIS PHARMACEUTICALS INC. (US) 2011-05-17 US disclosed
EP-2233486-A1 Azaindoles Aventis Pharma Limited (GB) 2010-09-29 EP disclosed
US-20050267304-A1 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders AVENTIS PHARMACEUTICALS INC. (US) 2005-12-01 US disclosed
US-6897207-B2 Azaindoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 US disclosed
US-20040053931-A1 Azaindoles AVENTIS PHARMACEUTICALS INC. 2004-03-18 US disclosed
EP-1397360-A1 AZAINDOLES Aventis Pharma Limited (GB) 2004-03-17 EP disclosed
WO-2003000688-A1 AZAINDOLES AVENTIS PHARMA LIMITED (GB) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053931-A1 Azaindoles CDKN1A, CDK7, CDK2 JAK2 337/4885LCK 155/4885IGF1R 1574/4885
US-20050267304-A1 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders MAP3K20, MAP3K12, MAP3K19 JAK2 345/4885LCK 66/4885IGF1R 1245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.